Obsessive-Compulsive Disorder

New England Journal of Medicine

Volumn 350, Issue 3, 2004, Pages 259-265

  Jenike, Michael A ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CLONAZEPAM;

ACCOMMODATION PARALYSIS; ADULT; ANXIETY DISORDER; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CASE REPORT; CLINICAL FEATURE; COGNITIVE THERAPY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; FEMALE; HEADACHE; HUMAN; INSOMNIA; LIBIDO DISORDER; MUSCLE WEAKNESS; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; VISUAL IMPAIRMENT; WITHDRAWAL SYNDROME; XEROSTOMIA; CHILD; MULTIMODALITY CANCER THERAPY; PRACTICE GUIDELINE;

ADULT; CHILD; CLONAZEPAM; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; FEMALE; GABA MODULATORS; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PRACTICE GUIDELINES; SEROTONIN UPTAKE INHIBITORS;

EID: 1242287002     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMcp031002     Document Type: Review

References (56)

1. Diagnostic and statistical manual of mental disorders, 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994.
2. Fineberg NA, O'Doherty C, Rajagopal S, Reddy K, Banks A, Gale TM. How common is obsessive-compulsive disorder in a dermatology outpatient clinic? J Clin Psychiatry 2003;64:152-5.
3. Maj M, Sartorius N, Okasha A, Zohar J, eds. Obsessive-compulsive disorder. 2nd ed. Chichester, England: John Wiley, 2002.
4. The Expert Consensus Panel for Obsessive-Compulsive Disorder. Treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58:Suppl 4:2-72.
5. Pauls DL, Alsobrook JP II, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. Am J Psychiatry 1995;152:76-84.
6. Carey G, Gottesman I. Twin and family studies of anxiety, phobic, and obsessive disorders. In: Klein DF, Rabkin JG, eds. Anxiety: new research and changing concepts. New York: Raven Press, 2000:117-36.
7. Alsobrook JP II, Pauls DL. The genetics of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-compulsive disorders: practical management. 3rd ed. St. Louis: Mosby, 1998:276-88.
8. Nestadt G, Samuels J, Riddle M, et al. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:358-63.
9. Nicolini H, Hanna G, Baxter L Jr, Schwartz J, Weissbacker K, Spence MA. Segregation analysis of obsessive compulsive and associated disorders. Ursus Medicus 1991;1:25-8.
10. Cavallini MC, Pasquale L, Bellodi L, Smeraldi E. Complex segregation analysis for obsessive compulsive disorder and related disorders. Am J Med Genet 1999;88:38-43.
11. Cavallini MC, Bertelli S, Chiapparino D, Riboldi S, Bellodi L. Complex segregation analysis of obsessive-compulsive disorder in 141 families of eating disorder probands, with and without obsessive-compulsive disorder. Am J Med Genet 2000;96:384-91.
12. Nestadt G, Lan T, Samuels J, et al. Complex segregation analysis provides compelling evidence for a major gene underlying obsessive-compulsive disorder and for heterogeneity by sex. Am J Med Genet 2000;67:1611-6.
13. Jenike MA, Baer L, Minichiello WE, eds. Obsessive-compulsive disorders: practical management. 3rd ed. St. Louis: Mosby, 1998.
14. Steketee GS. Treatment of obsessive compulsive disorder. New York: Guilford Press, 1993.
15. Swinson RP, Antony MM, Rachman S, Richter MA. Obsessive-compulsive disorder: theory, research, and treatment. New York: Guilford Press, 1998.
16. Jenike MA. Obsessive-compulsive disorder: efficacy of specific treatments as assessed by controlled trials. Psychopharmacol Bull 1993;29:487-99.
17. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive compulsive disorder. J Clin Psychiatry 1992;53:Suppl: 29-37.
18. Jenike MA. Augmentation strategies for treatment-resistant obsessive-compulsive disorder. Harv Rev Psychiatry 1993;1:17-26.
19. Fallon BA, Liebowitz MR, Campeas R, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998;55:918-24.
20. Foa EB, Franklin ME, Moser J. Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination? Biol Psychiatry 2002;52:987-97.
21. Lindsay M, Crino R, Andrews G. Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br J Psychiatry 1997;171:135-9.
22. Hohagen F, Winkelmann G, Rasche-Ruchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo: results of a multicentre study. Br J Psychiatry Suppl 1998;35:71-8.
23. O'Connor K, Todorov C, Robillard S, Borgeat F, Brault M. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study. Can J Psychiatry 1999;44:64-71.
24. Steketee G, Frost RO. Obsessive-compulsive disorder. In: Salkovskis P, ed. Comprehensive clinical psychology. Vol. 6. Adults: clinical formulation and treatment. New York: Pergamon Press, 1998.
25. Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ, Henk HJ. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology (Berl) 1998;136:205-16.
26. von Balkom AJLM, van Oppen P, Vermeulen AWA, van Dyck R, Nauta MCE, Vorst HCM. A meta-analysis on the treatment of obsessive-compulsive disorder: a comparison of antidepressants, behavior, and cognitive therapy. Clin Psychol Rev 1994;14:359-81.
27. Marks IM, Hodgson R, Rachman S. Treatment of chronic obsessive-compulsive neurosis by in-vivo exposure: a two-year follow-up and issues in treatment. Br J Psychiatry 1975;127:349-64.
28. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997;65:44-52.
29. Foa EB, Franldin ME. Psychotherapies for obsessive compulsive disorder: a review. In: Maj M, Sartorius N, Okasha A, Zohar J, eds. Obsessive-compulsive disorder. 2nd ed. Chichester, England: John Wiley, 2002:93-115.
30. Dougherty D, Rauch SL. Serotonin-reuptake inhibitors in the treatment of OCD. In: Hollander E, Stein DJ, eds. Obsessive-compulsive disorders: diagnosis, etiology, treatment. New York: Marcel Dekker, 1997:145-60.
31. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999;60:101-6.
32. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1521-5.
33. Fontaine R, Chouinard G. Fluoxetine in the long-term maintenance treatment of obsessive compulsive disorder. Psychiatr Ann 1989;19:88-91.
34. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:922-7.
35. Pato MT, Chakravorty S. Discontinuation and long-term treatment of obsessive-compulsive disorder. In: Jenike MA, Baer L, Minichiello WE, eds. Obsessive-compulsive disorders: practical management. 3rd ed. St. Louis: Mosby, 1998:625-46.
36. Pato MT, Hill JL, Murphy DL. A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. Psychopharmacol Bull 1990;26:211-4.
37. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol 1997;17:4-10. [Errata, J Clin Psychopharmacol 1997;17:340, 436.]
38. Mundo E, Bareggi SR, Pirola R, Bellodi L, Smeraldi E. Long-term pharmacotherapy of obsessive-compulsive disorder: a double-blind controlled study. J Clin Psychopharmacol 1997;17:4-10. [Errata, J Clin Psychopharmacol 1997;17:340, 436.]
39. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32:167-73.
40. Steiner M, Bushnell MS, Gergel IP. Long-term treatment and prevention of relapse of OCD with paroxetine. Presented at the 148th Annual Meeting of the American Psychological Association, New York, August 14, 1995. paper.
41. McDougle CJ, Goodman WK. Combination pharmacological treatment strategies. In: Hollander E, Stein DJ, eds. Obsessive-compulsive disorders: diagnosis, etiology, treatment. New York: Marcel Dekker, 1997:203-23.
42. Rauch SL, Jenike MA. Management of treatment resistant obsessive-compulsive disorder: concepts and strategies. In: Berend B, Hollander E, Marazitti D, Zohar J, eds. Current insights in obsessive-compulsive disorder. Chichester, England: John Wiley, 1994:227-44.
43. Rauch SL, Baer L, Jenike MA. Treatment-resistant obsessive-compulsive disorder: practical strategies for management. In: Pollack MH, Otto MW, Rosenbaum JF, eds. Challenges in clinical practice: pharmacologic and psychosocial strategies. New York: Guilford, 1996:201-18.
44. Hewlett W, Vinogradov S, Agras W. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992;12:420-30.
45. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991;11:175-84.
46. Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:242-8.
47. Harvey KV, Balon R. Augmentation with buspirone: a review. Ann Clin Psychiatry 1995;7:143-7.
48. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000;10:165-9.
49. Shapira NA, Keck PE Jr, Goldsmith TD, McConville BJ, Eis M, McElroy SL. Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder. Depress Anxiety 1997;6:170-3.
50. Goldsmith TD, Shapira NA, Keck PE Jr. Rapid remission of OCD with tramadol hydrochloride. Am J Psychiatry 2000;157:839.
51. Pato MT, Pigott TA, Hill JL, Grover GN, Bernstein S, Murphy DL. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1991;148:127-9.
52. Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261-4.
53. Cosgrove GR, Rauch SL. Psychosurgery. Neurosurg Clin N Am 1995;6:167-76.
54. Gabriels L, Cosyns P, Nuttin B, Demeulemeester H, Gybels J. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand 2003;107:275-82.
55. Greenberg BD, George MS, Martin JD, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry 1997;154:867-9.
56. Gravitz HL. Obsessive compulsive disorder: new help for the family. Santa Barbara, Calif.: Healing Visions Press, 1998.